




HEPENDO

First-line liver inflammatory protection


Hependo Sp. z o.o.

- ▶ Hependo Company was established in 2011
- ▶ Continuation of the Trigendo company (est. 2007) – one of the first tech. transfers from academia to business
- ▶ Shareholders of Trigendo are now participants of Hependo
- ▶ All of the Trigendo assets have been transferred into Hependo:
 - ▶ Patent (US) and patent applications, know how of the use of the API in:
 - ▶ Drug development
 - ▶ Dietary supplements
 - ▶ Cosmetics




Focus


- ▶ Liver inflammatory caused primarily by hepatitis C virus (HCV)
- ▶ Unmet medical need – poor success with current treatment
 - ▶ INF- α
 - ▶ Ribavirin
- ▶ Market size:
 - ▶ 2009 – \$4.4 B
 - ▶ 2016 – \$8.5 B (Estimated)




Business model



Current status



Development plan



Financing

- ▶ Currently Hependo closes up Stage I of financing: 200 000 €
 - ▶ Preclinical (nonGLP) supplementary data
- ▶ Stage II budget (expected): 4 M €
 - ▶ GLP tox and CMC
 - ▶ Filing IND application
 - ▶ Accomplishment of PI CT
- ▶ Stage III budget (expected): 10-15 M €
 - ▶ PII A CT



Thank you

Łukasz Kutrzeba

Lukasz.kutrzeba@hependo.pl

+48 5 15 075 500